Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury

Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase. It was approved by the Food and Drug Administration for the treatment of intermittent claudication. Its principal actions include inhibition of platelet aggregation, antith...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:CNS Neurosci Ther
Main Authors: Lee, Jeong Hyun, Park, So Youn, Shin, Hwa Kyoung, Kim, Chi Dae, Lee, Won Suk, Hong, Ki Whan
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Inc 2008
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494013/
https://ncbi.nlm.nih.gov/pubmed/18482026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2008.00042.x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki